Unliganded estrogen receptor-β regulation of genes is inhibited by tamoxifen

Molecular and Cellular Endocrinology

Volumn 315, Issue 1-2, 2010, Pages 201-207

  Levy, Nitzan ^a   Paruthiyil, Sreenivasan ^a   Zhao, Xiaoyue ^b   Vivar, Omar I ^a   Saunier, Elise F ^b   Griffin, Chandi ^a   Tagliaferri, Mary ^b   Cohen, Isaac ^b   Speed, Terence P ^c,d   Leitman, Dale C ^a,c  

^a Center for Reproductive Sciences   (United States)

^b Bionovo Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Estrogen receptor; Gene regulation; Microarray; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

DOXYCYCLINE; ESTROGEN RECEPTOR BETA; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2E; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PROMOTER REGIONS, GENETIC; TAMOXIFEN;

EID: 71849103610     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.08.030     Document Type: Article

References (44)

1. An J., Ribeiro R.C., Webb P., Gustafsson J.A., Kushner P.J., Baxter J.D., and Leitman D.C. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15161-15166
2. An J., Tzagarakis-Foster C., Scharschmidt T.C., Lomri N., and Leitman D.C. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276 (2001) 17808-17814
3. Ball L.J., Levy N., Zhao X., Griffin C., Tagliaferri M., Cohen I., Ricke W.A., Speed T.P., Firestone G.L., and Leitman D.C. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol. Cell. Endocrinol. 299 (2009) 204-211
4. Burakov D., Crofts L.A., Chang C.P., and Freedman L.P. Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J. Biol. Chem. 277 (2002) 14359-14362
5. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38 (2006) 1289-1297
6. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Colleoni M., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25 (2007) 486-492
7. Cui Y., Parra I., Zhang M., Hilsenbeck S.G., Tsimelzon A., Furukawa T., Horii A., Zhang Z.Y., Nicholson R.I., and Fuqua S.A. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 66 (2006) 5950-5959
8. Cvoro A., Tatomer D., Tee M.K., Zogovic T., Harris H.A., and Leitman D.C. Selective estrogen receptor-agonists repress transcription of proinflammatory genes. J. Immunol. 180 (2008) 630-636
9. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14863-14868
10. Fisher B., Dignanm J., Bryant J., Wickerman D., Deschenes L., Constantino J., Redmond C., Fisher E., Bowman D., Deschenes L., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 88 (1996) 1529-1542
11. Frasor J., Chang E.C., Komm B., Lin C.Y., Vega V.B., Liu E.T., Miller L.D., Smeds J., Bergh J., and Katzenellenbogen B.S. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 66 (2006) 7334-7340
12. Hall J.M., and McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 (1999) 5566-5578
13. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87 (2007) 905-931
14. Hewitt S.C., Harrell J.C., and Korach K.S. Lessons in estrogen biology from knockout and transgenic animals. Annu. Rev. Physiol. 67 (2005) 285-308
15. Hodges-Gallagher L., Valentine C.D., El Bader S., and Kushner P.J. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res. Treat. 109 (2008) 241-250
16. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., and Tobias J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
17. Hurvitz S.A., and Pietras R.J. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 113 (2008) 2385-2397
18. Improta-Brears T., Whorton A.R., Codazzi F., York J.D., Meyer T., and McDonnell D.P. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4686-4691
19. Jin S., Tong T., Fan W., Fan F., Antinore M.J., Zhu X., Mazzacurati L., Li X., Petrik K.L., Rajasekaran B., et al. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21 (2002) 8696-8704
20. Kian Tee M., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., Yamamoto K.R., and Leitman D.C. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors {alpha} and {beta}. Mol. Biol. Cell 15 (2004) 1262-1272
21. Krege J.H., Hodgin J.B., Couse J.F., Enmark E., Warner M., Mahler J.F., Sar M., Korach K.S., Gustafsson J.A., and Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15677-15682
22. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5925-5930
23. Lazennec G., Bresson D., Lucas A., Chauveau C., and Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 (2001) 4120-4130
24. Levy N., Tatomer D., Herber C.B., Zhao X., Tang H., Sargeant T., Ball L.J., Summers J., Speed T.P., and Leitman D.C. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol. Endocrinol. 22 (2008) 287-303
25. Levy N., Zhao X., Tang H., Jaffe R.B., Speed T.P., and Leitman D.C. Multiple transcription factor elements collaborate with estrogen receptor {alpha} to activate an inducible estrogen response element in the NKG2E gene. Endocrinology 148 (2007) 3449-3458
26. Lonard D.M., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators and human disease. Endocr. Rev. 28 (2007) 575-587
27. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., and Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11162-11166
28. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
29. Murphy L.C., and Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 13 (2006) 327-334
30. Ohki R., Nemoto J., Murasawa H., Oda E., Inazawa J., Tanaka N., and Taniguchi T. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J. Biol. Chem. 275 (2000) 22627-22630
31. Paech K., Webb P., Kuiper G., Nilsson S., Gustafsson J.-A., Kushner P., and Scanlan T. Differential ligand activation of estrogen receptors ERa and ERb at API sites. Science 277 (1997) 1508-1510
32. Paruthiyil S., Cvoro A., Zhao X., Wu Z., Sui Y., Staub R.E., Baggett S., Herber C.B., Griffin C., Tagliaferri M., et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS ONE 4 (2009) e6271
33. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64 (2004) 423-428
34. Power R.F., Mani S.K., Codina J., Conneely O.M., and O'Malley B.W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254 (1991) 1636-1639
35. Shaaban A.M., O'Neill P.A., Davies M.P., Sibson R., West C.R., Smith P.H., and Foster C.S. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol. 27 (2003) 1502-1512
36. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
37. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
38. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 (2004) 45-71
39. Speirs V., and Walker R. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J. Pathol. 211 (2007) 499-506
40. Strom A., Hartman J., Foster J.S., Kietz S., Wimalasena J., and Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1566-1571
41. Thomas R.S., Sarwar N., Phoenix F., Coombes R.C., and Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J. Mol. Endocrinol. 40 (2008) 173-184
42. Vivar O.I., Lin C.L., Firestone G.L., and Bjeldanes L.F. 3,3′-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem. Pharm. 78 (2009) 469-476
43. Wu Z., and Irizarry R.A. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J. Comput. Biol. 12 (2005) 882-893
44. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., and Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312 (2006) 902-906